Skip to main content
Terug
Watch Compare

Coherus Oncology, Inc.

Datakwaliteit: 83%
CHRS
Nasdaq Manufacturing Chemicals
€ 1,66
▼ € 0,05 (-2,65%)
Marktkapitalisatie: 248,07 M
Prijs
€ 1,66
Marktkapitalisatie
248,07 M
Dagbereik
€ 1,61 — € 1,70
52-Weeksbereik
€ 0,71 — € 2,62
Volume
787.617
Openen € 1,69
50D / 200D Gem.
€ 1,83
9,71% below
50D / 200D Gem.
€ 1,42
16,61% above

Quick Summary

Belangrijkste Punten

Earnings grew 489,41% over the past year
ROE of 161,87% indicates high profitability
Negative free cash flow of -138,51 M
P/E of 1,48 — trading at a low valuation

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)489,41%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
161,87%
Boven sectorgemiddelde (-51,02%)
ROIC-89,42%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio1,24
Interest Coverage-20,12

Waardering

PE (TTM)
1,48
Boven sectorgemiddelde (-1,98)
P/B Ratio2,83
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (44 peers)
Metriek Aandeel Sector Mediaan
P/E 1,5 -2,0
P/B 2,8 5,1
ROE % 161,9 -51,0
Net Margin % — -150,2
Rev Growth 5Y % — 9,3
D/E — 0,3

ETFs Holding This Stock

EES logo EES WisdomTree U.S. SmallCap Fund
0,02% weight
IWV logo IWV iShares Russell 3000 ETF
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) 489,41% Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) 168,02 M
ROE 161,87% ROA 35,15%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -138,51 M
ROIC -89,42% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1,24
Interest Coverage -20,12 Asset Turnover N/A
Working Capital 88,66 M Tangible Book Value 67,15 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 1,48 Forward P/E N/A
P/B Ratio 2,83 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -55,84%
Market Cap 248,07 M Enterprise Value 144,72 M
Per Share
EPS (Diluted TTM) 1,43 Revenue / Share N/A
FCF / Share -0,92 OCF / Share -0,92
EPS CAGR (1Y) 472,00% EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion -82,44%
SBC-Adj. FCF -159,56 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income 168,02 M 28,51 M -237,89 M -291,75 M -287,10 M
EPS (Diluted) 1,43 0,25 -2,53 -3,76 -3,81
Gross Profit — — — — —
Operating Income -181,13 M -111,67 M -203,20 M -256,88 M -263,86 M
EBITDA — — — — —
R&D Expenses 108,89 M 93,34 M 109,44 M 199,36 M 363,11 M
SG&A Expenses 100,60 M 167,74 M 192,02 M 198,48 M 169,71 M
D&A 1,30 M 1,80 M 3,20 M 3,70 M 3,45 M
Interest Expense 9,00 M 27,16 M 40,54 M 32,47 M 22,96 M
Income Tax 0,0 -380.000,0 -380.000,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 258,34 M 448,53 M 629,60 M 480,85 M 679,33 M
Total Liabilities 197,33 M 580,52 M 823,03 M 618,27 M 581,61 M
Shareholders' Equity 61,01 M -131,99 M -193,43 M -137,42 M 97,73 M
Total Debt — — — — —
Cash & Equivalents 88,88 M 125,99 M 102,89 M 63,55 M 417,20 M
Current Assets 206,71 M 341,58 M 475,63 M 381,23 M 602,32 M
Current Liabilities 140,39 M 282,98 M 331,77 M 138,69 M 165,33 M